Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. COLL
COLL logo

COLL Valuation

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Historical Valuation

Collegium Pharmaceutical Inc (COLL) is now in the Overvalued zone, suggesting that its current forward PE ratio of 6.01 is considered Overvalued compared with the five-year average of 4.61. The fair price of Collegium Pharmaceutical Inc (COLL) is between 25.28 to 34.87 according to relative valuation method. Compared to the current price of 35.62 USD , Collegium Pharmaceutical Inc By Overvalued By 2.16%.
Relative Value
Fair Zone
25.28-34.87
Current Price:35.62
2.16%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Unlock 5-Year Valuation Change
Is Collegium Pharmaceutical Inc (COLL) at a historical peak or a rare bargain? Access the full 5-year trend to find out.
Unlock Now
Collegium Pharmaceutical Inc (COLL) has a current Price-to-Book (P/B) ratio of 5.24. Compared to its 3-year average P/B ratio of 4.67, the current P/B ratio is approximately 12.08% higher. Relative to its 5-year average P/B ratio of 4.17, the current P/B ratio is about 25.67% higher. Collegium Pharmaceutical Inc (COLL) has a Forward Free Cash Flow (FCF) yield of approximately 20.10%. Compared to its 3-year average FCF yield of 23.82%, the current FCF yield is approximately -15.62% lower. Relative to its 5-year average FCF yield of 19.29%, the current FCF yield is about 4.18% lower.

Competitors Valuation Multiple

AI Analysis
The average P/S ratio for COLL competitors is 640.43, providing a benchmark for relative valuation. Collegium Pharmaceutical Inc Corp (COLL.O) exhibits a P/S ratio of 1.80, which is -99.72% above the industry average. Given its robust revenue growth of 12.92%, this premium appears unsustainable.
P/E
P/S
EV/EBITDA
EV/EBIT
Earnings Growth
Market Cap

Performance Decomposition

AI Analysis
1Y
3Y
5Y
Market capitalization of COLL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00% to the performance.
Overall, the performance of COLL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is COLL currently overvalued or undervalued?

Collegium Pharmaceutical Inc (COLL) is now in the Overvalued zone, suggesting that its current forward PE ratio of 6.01 is considered Overvalued compared with the five-year average of 4.61. The fair price of Collegium Pharmaceutical Inc (COLL) is between 25.28 to 34.87 according to relative valuation method. Compared to the current price of 35.62 USD, Collegium Pharmaceutical Inc is Overvalued By 2.16%.

What is Collegium Pharmaceutical Inc (COLL) fair value?

COLL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Collegium Pharmaceutical Inc (COLL) is between 25.28 to 34.87 according to relative valuation method.

How does COLL's valuation metrics compare to the industry average?

The average P/S ratio for COLL's competitors is 640.43, providing a benchmark for relative valuation. Collegium Pharmaceutical Inc Corp (COLL) exhibits a P/S ratio of 1.80, which is -99.72% above the industry average. Given its robust revenue growth of 12.92%, this premium appears unsustainable.

What is the current P/B ratio for Collegium Pharmaceutical Inc (COLL) as of Mar 12 2026?

As of Mar 12 2026, Collegium Pharmaceutical Inc (COLL) has a P/B ratio of 5.24. This indicates that the market values COLL at 5.24 times its book value.

What is the current FCF Yield for Collegium Pharmaceutical Inc (COLL) as of Mar 12 2026?

As of Mar 12 2026, Collegium Pharmaceutical Inc (COLL) has a FCF Yield of 20.10%. This means that for every dollar of Collegium Pharmaceutical Inc's market capitalization, the company generates 20.10 cents in free cash flow.

What is the current Forward P/E ratio for Collegium Pharmaceutical Inc (COLL) as of Mar 12 2026?

As of Mar 12 2026, Collegium Pharmaceutical Inc (COLL) has a Forward P/E ratio of 6.01. This means the market is willing to pay $6.01 for every dollar of Collegium Pharmaceutical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Collegium Pharmaceutical Inc (COLL) as of Mar 12 2026?

As of Mar 12 2026, Collegium Pharmaceutical Inc (COLL) has a Forward P/S ratio of 1.80. This means the market is valuing COLL at $1.80 for every dollar of expected revenue over the next 12 months.